Outset Medical (NASDAQ:OM) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of Outset Medical (NASDAQ:OM) from a hold rating to a sell rating in a research report sent to investors on Saturday.

Other analysts also recently issued research reports about the company. BTIG Research reissued a “buy” rating and issued a $17.00 price target on shares of Outset Medical in a report on Tuesday, December 16th. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $7.00 target price on shares of Outset Medical in a research report on Wednesday, December 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Outset Medical in a research note on Monday, December 29th. Finally, Stifel Nicolaus lowered their price target on shares of Outset Medical from $14.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, January 7th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $10.67.

Outset Medical Stock Performance

Shares of NASDAQ OM opened at $5.57 on Friday. The company has a quick ratio of 5.77, a current ratio of 7.09 and a debt-to-equity ratio of 0.69. The firm’s 50-day moving average price is $5.06 and its two-hundred day moving average price is $11.71. Outset Medical has a 52-week low of $3.10 and a 52-week high of $21.98. The stock has a market capitalization of $101.10 million, a P/E ratio of -0.43 and a beta of 2.07.

Institutional Investors Weigh In On Outset Medical

Hedge funds and other institutional investors have recently modified their holdings of the stock. Pura Vida Investments LLC grew its position in Outset Medical by 8,482.4% in the 2nd quarter. Pura Vida Investments LLC now owns 429,120 shares of the company’s stock valued at $8,243,000 after buying an additional 424,120 shares in the last quarter. Assenagon Asset Management S.A. acquired a new stake in shares of Outset Medical in the 3rd quarter worth approximately $5,324,000. Geode Capital Management LLC lifted its stake in shares of Outset Medical by 955.9% in the 2nd quarter. Geode Capital Management LLC now owns 415,552 shares of the company’s stock worth $7,984,000 after acquiring an additional 376,196 shares during the period. Millennium Management LLC boosted its holdings in shares of Outset Medical by 165.8% in the third quarter. Millennium Management LLC now owns 421,409 shares of the company’s stock valued at $5,950,000 after acquiring an additional 262,874 shares in the last quarter. Finally, Ensign Peak Advisors Inc increased its stake in shares of Outset Medical by 272.4% during the second quarter. Ensign Peak Advisors Inc now owns 314,522 shares of the company’s stock valued at $6,042,000 after acquiring an additional 230,065 shares during the period.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long?term care facilities and emergency response scenarios.